Biotron Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
842.70
17.00
15.50
13.10
11.60
Gross Income
842.70
17.00
15.50
13.10
11.60
SG&A Expense
3,696.50
4,114.80
4,307.40
4,383.20
2,969.90
EBIT
4,878.30
4,131.80
4,322.80
4,396.30
2,981.60
Non Operating Income/Expense
1,722.50
311.40
306.10
340.50
250.30
Pretax Income
3,085.80
4,395.50
4,552.50
4,707.10
3,215.30
Income Tax
-
1,672.30
1,548.20
1,613.70
1,621.70
Consolidated Net Income
3,085.80
2,723.20
3,004.30
3,093.40
1,593.60
Net Income
3,085.80
2,723.20
3,004.30
3,093.40
1,593.60
Net Income After Extraordinaries
3,085.80
2,723.20
3,004.30
3,093.40
1,593.60
Net Income Available to Common
3,085.80
2,723.20
3,004.30
3,093.40
1,593.60
EPS (Basic)
0.01
0.01
0.01
0.01
0.00
Basic Shares Outstanding
280,865.40
301,502.30
361,849.70
365,699.80
397,150.10
EPS (Diluted)
0.01
0.01
0.01
0.01
0.00
Diluted Shares Outstanding
280,865.40
301,502.30
361,849.70
365,699.80
397,150.10
EBITDA
4,867.10
4,114.80
4,307.40
4,383.20
2,969.90
Other Operating Expense
339.00
-
-
-
-
Non-Operating Interest Income
70.00
47.70
76.40
29.60
16.60

About Biotron

View Profile
Address
56 Delhi Road
North Ryde New South Wales (NSW) 2113
Australia
Employees -
Website http://www.biotron.com.au
Updated 07/08/2019
Biotron Ltd. is a clinical stage Australian biotechnology company. It engages in developing and commercializing a novel small molecule approach that has the potential to treat a number of serious viral diseases. The company's technology targets viroporin proteins, which are key to enabling the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus.